by Jordana Choucair | Aug 25, 2022 | Life Sciences
Democratic lawmakers on the House Select Subcommittee on the Coronavirus Crisis released a report indicating that senior Trump administration officials leaned on Food and Drug Administration (FDA) Commissioner Stephen Hahn and other agency leaders to sign off on...
by Jordana Choucair | Aug 25, 2022 | Life Sciences
A large Israeli study found that Pfizer Inc.’s COVID-19 treatment Paxlovid lowered hospitalization rates in 65-year-olds and older by about 75 percent. However, people ages 40-64 who took the drug shortly after infection saw little to no benefit. The study was...
by Jordana Choucair | Aug 25, 2022 | Opioid/Substance Use Disorders
A Legal Action Center study found that adding more coverage of substance use disorders (SUD) to Medicare will only slightly raise federal spending. Researchers found that if Medicare decided to extend coverage to include all SUD therapies, providers, and setting, it...
by Jordana Choucair | Aug 25, 2022 | Payers
Altarum released a new analysis indicating that there is a widening divergence between Medicare and private sector health care prices. According to the analysis, Medicare prices fell by almost an entire percentage point in July due to low or no increases in the...
by Jordana Choucair | Aug 25, 2022 | Providers
Amazon announced that it will shutdown its Amazon Care service for employers after December 31. Amazon piloted the virtual urgent care and primary care offering with its employees and their families in the Seattle region in 2019 and expanded nationwide thereafter....
by Jordana Choucair | Aug 24, 2022 | Life Sciences
Moderna submitted a request for the Food and Drug Administration (FDA) to authorize an updated version of its COVID-19 vaccine targeting the latest omicron subvariants. The company said the shots will be ready to ship in September, if the FDA signs off. Moderna’s...
Recent Comments